Titan Medical debuts Sport robot assisted surgery prototype

Titan Medical (CVE:TMD) yesterday introduced the prototype of its Sport robot-assisted surgery device to investors in New York as it gears up for 1st-in-human trials this year. Titan is chasing TransEnterix (NYSE:TRXC) in the race to challenge robot-assisted surgery’s dominant player, Intuitive Surgical (NSDQ:ISRG), and its da Vinci system. TransEnterix’s SurgiBot is expected to hit the U.S. market during the 1st half of this year; Titan’s Sport offering is anticipated for mid-2017. Late-comers to the space include the Verb joint venture between Johnson & Johnson (NYSE:JNJ) and Google (NSDQ:GOOG) subsidiary Verily Life Sciences; a still-unnamed device from Medtronic (NYSE:MDT); and stealthy Auris Surgical Robotics, led by Intuitive founder Dr. Frederic Moll. Leerink Partners analysts Richard Newitter and Ravi Misra wrote yesterday that Titan’s Sport prototype, the 1st and only system the company’s made thus far, seems to resemble the next-generation da Vinci Sp system Intuitive is developing. At an estimated price of $800,000 with consumables priced “more in line with traditional laparoscopic instrumentation,” Titan management told the analysts, the Sport system will undercut da Vinci. “While early commercialization efforts would include academic institutions, we believe ultimately the company’s sales funnel could lean toward smaller community hospitals where Sport could offer a lower cost of acquisition vs...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Robot-Assisted Surgery Wall Street Beat Intuitive Surgical Inc. Titan Medical Inc. Source Type: news